10-K/A: Solsence Restates 2025 Financials Amidst Internal Control Weaknesses

Solsence, Inc. has filed an amendment to its 2025 annual report to restate its consolidated financial statements due to errors in inventory accounting, revealing material weaknesses in internal controls.

Summary

• Solsence, Inc. (formerly Nanophase Technologies Corporation) has filed an amendment (10-K/A) to its 2025 annual report to restate its audited consolidated financial statements for the fiscal year ended December 31, 2025.
• The restatement is due to errors identified in historical accounting for labor and overhead included in inventories, which led to overstatements in inventory and misstatements in the cost of revenue.
• These errors affected gross profit, operating income, net income, earnings per share, and equity.
• As a result, the company's previously issued consolidated financial statements for 2023, 2024, and 2025, as well as interim periods, can no longer be relied upon.
• Management identified material weaknesses in inventory costing and in the oversight and review of financial reporting and restatement activities, leading to a conclusion that internal controls were not effective as of December 31, 2025.
• The company is implementing remediation plans for these control deficiencies.
• In connection with the restatement, the company is recovering $252,785 of erroneously awarded incentive-based compensation from current and former executive officers.
• Total revenue for 2025 was $62,064,000, an increase from $52,347,000 in 2024, driven primarily by consumer products.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant restatement of financial statements, material weaknesses in internal controls, and the recovery of incentive-based compensation, despite some revenue growth.

Positives

• Total revenue increased to $62,064,000 in 2025 from $52,347,000 in 2024, representing a significant year-over-year growth.
• Gross profit, as restated, increased to $17,082,000 in 2025 from $13,052,000 in 2024, with gross margin improving to approximately 27.5% from 24.9%.
• Net income, as restated, increased to $2,809,000 in 2025 from $1,099,000 in 2024.
• The company has a positive gross margin at current revenue levels.
• The company expects its current fixed manufacturing cost structure to support higher revenue volumes, potentially leading to increased margins.
• The company received a payment of $1,729,000 from the U.S. Department of the Treasury under the Employee Retention Credit (ERC) program, plus $272,000 in interest.

Negatives

• The company is restating its previously issued consolidated financial statements for 2023, 2024, and 2025 due to errors in inventory accounting.
• Material weaknesses were identified in inventory costing and in the oversight and review of financial reporting and restatement activities, rendering internal controls ineffective as of December 31, 2025.
• The company must recover $252,785 of erroneously awarded incentive-based compensation from executive officers due to performance metrics not meeting thresholds.
• Net cash used in operating activities was $8,567,000 in 2025, a significant decrease from $1,971,000 provided by operating activities in 2024.
• The company's largest customers represent a substantial majority of its revenue, with the top three customers accounting for 55% of revenue in 2025.
• The company has a significant accumulated deficit of $102,270,000 as of December 31, 2025.
• The company has federal net operating loss carryforwards of approximately $38.5 million, with $30.7 million expiring between 2026 and 2038.

Risks

• The company's reliance on a few significant customers poses a risk if those relationships are disrupted.
• Inflationary pressures on supplier prices and wages are expected to have a material effect on operations and financial position in 2026 and beyond.
• The company may not be able to pass on cost increases to customers due to contractual limitations or market conditions, which could reduce margins and net income.
• The company's ability to utilize its net operating loss carryforwards may be subject to limitations due to potential future ownership changes.
• The IRS reserves the right to audit ERC payments, creating a contingent liability of $572,000.
• The company could lose significant revenue if its exclusive supply agreement with BASF is terminated due to failure to meet performance requirements, potentially leading to the sale of production equipment.

Future Outlook

The company expects expenses for research and development to remain about the same or decrease slightly in 2026. SG&A expenses are expected to be slightly lower in 2026 due to cost controls. The company anticipates inflationary pressures on supplier prices and wages may have a material effect in 2026 and beyond, and will attempt to pass these costs on to customers. Capital expenditures for 2026 are projected to be between $1 million and $3 million, funded by operations, existing credit, and potential new financing.

Management Comments

• While we have seen costs continue to increase on an inflationary basis as we enter 2026, it is our belief that we will be able to offset much of this cost as we gain greater production efficiencies and seek to increase our pricing where possible.
• We believe that our current fixed manufacturing cost structure is sufficient to support higher levels of revenue volume.
• We expect that, as product revenue volume increases, our fixed manufacturing costs will be more efficiently absorbed, which should lead to increased margins as we grow.
• We expect to continue to focus on reducing controllable variable product manufacturing costs, with potential variability related to the commodity metals markets and cost and wage inflation but may or may not realize gross margin percentage growth through 2026 and beyond, dependent upon the factors discussed above.
• We expect expenses for research and development to remain about the same or decrease slightly in 2026 depending on growth in our consumer products, and related technologies.
• We expect 2026 expenses in this area to be slightly lower due to controlling our administrative functions costs, including related staffing.
• We will apply our best efforts to pass through cost increases to our customers. If we are unable to pass through any increases due to contractual limitations or conditions in our markets specifically, this could reduce margins and net income.

Industry Context

StockSavvy.ai notes that Solsence operates in the health-oriented, science-driven markets of skin health, beauty, and wellness, with a focus on mineral-based UV protection and prestige skincare. The company also serves legacy markets in advanced materials. The restatement and internal control issues are significant internal matters that overshadow current market trends, but the company's focus on skin health aligns with broader consumer demand for such products.

Comparison to Industry Standards

• The restatement of financial statements due to inventory costing errors indicates a deviation from industry best practices for financial reporting and internal controls.
• The identified material weaknesses in inventory costing and financial reporting oversight suggest a lack of robust internal control frameworks compared to established industry standards.
• The recovery of incentive-based compensation due to performance metric shortfalls, while a regulatory requirement, highlights potential issues with compensation structure alignment with actual performance.
• The company's gross margin of 27.5% in 2025 is within a range that can be considered typical for some manufacturing sectors, but specific comparisons would require detailed analysis of sub-segments within consumer products, personal care ingredients, and advanced materials.
• The company's reliance on a few large customers (55% of revenue from top 3 in 2025) is a common risk factor in many industries, but the degree of concentration can be higher or lower than industry averages depending on the specific sector.

Management Changes

Legal Proceedings

• The company is recovering $252,785 of erroneously awarded incentive-based compensation from current and former executive officers due to performance metrics not meeting minimum thresholds for fiscal year 2024.
• The IRS has stated that they reserve the right to audit ERC payments for several years after they were requested, creating a contingent liability.

Related Party Transactions

• The company has loan agreements with Beachcorp, LLC and Strandler, LLC, which are affiliates of Mr. Bradford T. Whitmore, a majority shareholder and brother of director Ms. R. Janet Whitmore.
• These agreements include an Amended and Restated Business Loan Agreement (A&R Loan Agreement) and an Inventory Facility with Beachcorp, LLC, and a Term Loan Agreement with Strandler, LLC.
• The company issued Series X Preferred Stock to Strandler, LLC for $6,000,000.
• As of December 31, 2025, outstanding balances with Beachcorp, LLC were $14,267,000 and with Strandler, LLC were $1,000,000.

Stakeholder Impact

• Shareholders: The restatement of financial statements and material weaknesses in internal controls negatively impact investor confidence and may affect share price. The recovery of compensation also impacts executive compensation disclosures.
• Creditors: The company's financial position and control deficiencies could impact its ability to meet debt obligations, although the filing indicates ongoing efforts to manage debt facilities.
• Employees: While not explicitly detailed, the company's financial health and control environment can impact job security and morale. The recovery of compensation may also affect executive morale.
• Customers: The company's financial stability and operational integrity are crucial for maintaining customer relationships, especially given the concentration of revenue from a few key customers.

Next Steps

• Implement remediation measures for material weaknesses in inventory costing and financial reporting oversight.
• Continue to focus on reducing controllable variable product manufacturing costs.
• Seek recovery of remaining erroneously awarded incentive compensation from executive officers.
• Continue to develop new materials and dispersion technologies for personal care and consumer products.
• Manage capital expenditures for 2026, which are expected to be between $1 million and $3 million, funded by operations, credit facilities, and potential new financing.

Key Dates

Recommendation

The restatement of financial statements due to significant accounting errors, coupled with the identification of material weaknesses in internal controls, indicates a fundamental lack of reliability in the company's financial reporting. The need to recover incentive compensation further underscores internal control and performance issues. While revenue and gross profit showed improvement, these positives are overshadowed by the severity of the accounting and control failures, making the stock a sell until these issues are demonstrably resolved and trust in financial reporting is re-established.

Keywords

Solsence, 10-K/A, Restatement, Inventory Accounting, Internal Controls, Material Weakness, Executive Compensation, Financial Statements